Asitri Dashboard

Search Clinical Trials

The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.

Saved Searches

Choose Search
Basic Search
Targeted Search

Clinical Trials Search Results

Query: "AREA[SponsorSearch](Beijing InnoCare Pharma Tech Co., Ltd.)"
Count: 26
Selected: 0
NCT IDTitle
NCT05372120A Clinical Trial of ICP-192 in Treated Patients With Advanced Solid Tumors With FGF/FGFR Gene Alterations
NCT05370755A Study of ICP-189 and ICP-189 in Combination With Anti-PD-1 Monoclonal Antibody in Patients With Advanced Solid Tumors
NCT05367232A Study of ICP-033 in Patients With Advanced Solid Tumors
NCT05316857DDI Study of Orelabrutinib
NCT05234684A Study of Orelabrutinib Plus R-CHOP in Treatment-naïve Patients With MCD Subtype Diffuse Large B-cell Lymphoma
NCT05232149A Study to Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Immune Thrombocytopenia
NCT05210868A Phase I/II Study of CM355 in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL)
NCT05051891A Randomized, Open-label, Multi-center, Phase III Study of Orelabrutinib in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) vs. R-CHOP Alone in Patients With Treatment-naїve Mantle Cell Lymphoma
NCT04711148A Phase 2 Study of Orelabrutinib in Patients With Relapsing-Remitting Multiple Sclerosis
NCT04685226A Phase I/II Clinical Trial of ICP-723 in the Treatment of Advanced Solid Tumors
NCT04578613ICP-022 Versus Chlorambucil Combined With Rituximab in the Treatment of Untreated CLL/SLL
NCT04565275A Study of ICP-192 in Patients With Advanced Solid Tumors
NCT04492293An Efficacy and Safety Study of ICP-192 in Subjects With Bladder Urothelial Cancer
NCT04441450ADME Study of [14C]ICP-022 in Healthy Males
NCT04440059A Study of ICP-022 in the Treatment of Recurrent or Refractory Waldenstrom Macroglobulinemia
NCT04438044A Study to Evaluate ICP-022 in Patients With R/R PCNSL and SCNSL
NCT04438005A Study of ICP-022 in Patients With R/R DLBCL
NCT04305197A Study of ICP-022 in Patients With Systemic Lupus Erythematosus (SLE)
NCT04304040A Study of MIL62 Combined With Orelabrutinib for the Treatment of R/R CD20+B Cell Lymphoma
NCT04014205A Study of Tyrosine Kinase Inhibitor Orelabrutinib (ICP-022) in Patients With r/r B-Cell Malignancies
NCT03797456A Study to Evaluate ICP-022 in Patients With R/R Marginal Zone Lymphoma (MZL)
NCT03758664Clinical Study of ICP-192 in Solid Tumors Patients
NCT03642834Study of ICP-105 in Solid Tumors Patients
NCT03494179A Study to Evaluate ICP-022 in Patients With R/R Mantle Cell Lymphoma (MCL)
NCT03493217A Study to Evaluate ICP-022 in Patients With CLL/ SLL
NCT05284175A Study of Orelabrutinib in Patients With AQP4-IgG Positive Neuromyelitis Optica Spectrum Disorder